UNSPSC 51373004: Phenazocine

This classification denotes an opioid analgesic and narcotic with the molecular formula C22H27NO, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier J0ND6N0AQC, chemically known as 1,2,3,4,5,6-hexahydro-8-hydroxy-6,11-dimethyl-3-phenethyl-2,6-methano-3-benzazocine but generally known as phenazocine, which bears US NIH Compound Identifier 14707. European Medicines Agency schedules Phenazocine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09752MIG.

UNSPSC 51373004 Phenazocine is a Commodity code that in recent state and local procurement activity covers naloxone, safe drug deactivation systems, and broader multi-source generic pharmaceuticals and over-the-counter products supplied through authorized wholesalers to public health and human services agencies. State and local governments buy these products to support community health initiatives, emergency response programs, and pharmacy benefit programs serving employees, retirees, and covered populations. The issuing bodies include county health departments, state health and human services commissions, and multistate cooperative purchasing alliances that aggregate demand across participating state and local jurisdictions. Seminole County, Florida, the Texas Health and Human Services Commission, and the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) have posted recent opportunities under or near this code space, reflecting a mix of direct county procurement, state-level strategic sourcing, and cooperative contracting vehicles that leverage multistate purchasing power to negotiate volume pricing and standardized supplier relationships.

Recent activity spans Florida, Texas, Minnesota, and Oregon, with the multistate MMCAP RFP representing the broadest geographic footprint. Seminole County's IFB posted June 30, 2026, sought 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries and a July 26, 2023 response deadline. The Texas HHS Commission issued an RFI (HHS0017013) on April 3, 2026, to gather vendor capabilities for a Direct-to-Manufacturer Prescriptions program, exploring how state pharmacy benefit programs can establish relationships with pharmaceutical manufacturers outside traditional pharmacy benefit managers and wholesalers. MMCAP's RFP (S1070000015802), posted January 20, 2026, with a March 26, 2026 response deadline, establishes multistate contracts for generic multi-source pharmaceuticals and OTC products distributed through three authorized wholesalers—AmerisourceBergen Drug Corporation (Cencora), Cardinal Health 110 and 112, and Morris & Dickson Co., LLC—with awarded vendor agreements effective July 1, 2026. All MMCAP vendors must comply with current Good Manufacturing Practices, the Drug Supply Chain Security Act, and maintain commercial general liability insurance of $5,000,000 per occurrence.